Literature DB >> 7069227

Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae.

M L Clements, M M Levine, C R Young, R E Black, Y L Lim, R M Robins-Browne, J P Craig.   

Abstract

Sera from 147 volunteers were examined for vibriocidal antibody by the tube-dilution method before and after they ingested 10(3)-10(6) Vibrio cholerae organisms. Titers increased significantly after challenge in 97% of 110 persons who excreted V. cholerae. In 12% of the bacteriologically confirmed infections, the titer increased significantly only to the homologous (Inaba or Ogawa) serotype. Levels of vibriocidal antibody decreased substantially between one and six months after challenge, but they usually remained elevated over base-line values. Levels of antitoxin to V. cholerae were measured by IgG enzyme-linked immunosorbent assay (ELISA), rabbit skin permeability tests, and adrenal cell techniques in 73 pairs of prechallenge and postchallenge sera. Results of the vibriocidal assay agreed most closely with those of the ELISA, the most sensitive antitoxin assay, in serologically detecting clinical and subclinical infections. Recent infection could be accurately serodiagnosed by levels of vibriocidal antibody and antitoxin (by IgG ELISA) in a convalescent-phase serum.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7069227     DOI: 10.1093/infdis/145.4.465

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  53 in total

1.  Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.

Authors:  D N Taylor; J L Sanchez; J M Castro; C Lebron; C M Parrado; D E Johnson; C O Tacket; G A Losonsky; S S Wasserman; M M Levine; S J Cryz
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.

Authors:  K L Kotloff; S S Wasserman; S O'Donnell; G A Losonsky; S J Cryz; M M Levine
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

3.  Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infection.

Authors:  C O Tacket; R K Taylor; G Losonsky; Y Lim; J P Nataro; J B Kaper; M M Levine
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

4.  Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.

Authors:  D N Taylor; C O Tacket; G Losonsky; O Castro; J Gutierrez; R Meza; J P Nataro; J B Kaper; S S Wasserman; R Edelman; M M Levine; S J Cryz
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

5.  Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.

Authors:  S Migasena; P Pitisuttitham; B Prayurahong; P Suntharasamai; W Supanaranond; V Desakorn; U Vongsthongsri; B Tall; J Ketley; G Losonsky
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

6.  Frequency of reexposure to Vibrio cholerae O1 evaluated by subsequent vibriocidal titer rise after an episode of severe cholera in a highly endemic area in Bangladesh.

Authors:  Ana A Weil; Fahima Chowdhury; Ashraful I Khan; Daniel T Leung; Taher Uddin; Yasmin Ara Begum; Nirod Chandra Saha; Richelle C Charles; Regina C Larocque; Jason B Harris; Edward T Ryan; Firdausi Qadri; Stephen B Calderwood
Journal:  Am J Trop Med Hyg       Date:  2012-09-10       Impact factor: 2.345

7.  Diminished immunogenicity of a recombination-deficient derivative of Vibrio cholerae vaccine strain CVD103.

Authors:  J M Ketley; J B Kaper; D A Herrington; G Losonsky; M M Levine
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

8.  Human immune response to Vibrio cholerae O1 whole cells and isolated outer membrane antigens.

Authors:  K Richardson; J B Kaper; M M Levine
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

9.  Analysis of the Human Mucosal Response to Cholera Reveals Sustained Activation of Innate Immune Signaling Pathways.

Authors:  Firdausi Qadri; Jason B Harris; Daniel L Bourque; Taufiqur Rahman Bhuiyan; Diane P Genereux; Rasheduzzaman Rashu; Crystal N Ellis; Fahima Chowdhury; Ashraful I Khan; Nur Haq Alam; Anik Paul; Lazina Hossain; Leslie M Mayo-Smith; Richelle C Charles; Ana A Weil; Regina C LaRocque; Stephen B Calderwood; Edward T Ryan; Elinor K Karlsson
Journal:  Infect Immun       Date:  2018-01-22       Impact factor: 3.441

10.  Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin.

Authors:  R E Black; M M Levine; M L Clements; C R Young; A M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.